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Abstract. – Post-liver transplant intrahepatic 
cholestasis is consequent to the impairment of 
bile flow or formation. It may develop in the ear-
ly (within 6 months) or in the late (more than 6 
months) post-liver transplant period and differ-
ent causes may be recognized according to the 
time elapsed from a liver transplant. The raise 
at various degrees of serum bilirubin, alkaline 
phosphatase, and gamma-glutamyl transpep-
tidase, with or without increased transaminas-
es levels, are common hematochemical find-
ings. Liver histology is helpful for diagnostic 
assessment, and sometimes crucial to differen-
tiate among possible causes of cholestasis. Al-
though timely treatment of underling conditions 
as well as supportive care may resolve post-liv-
er transplant intrahepatic cholestasis, the risk of 
graft loss and retransplantation are remarkable. 
For this reason, post-liver transplant intrahepat-
ic cholestasis should be managed in collabora-
tion with the LT center, and treatment should be 
devolved to expert hepatologists.
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Introduction
Cholestasis is a condition characterized by de-
fective bile flow or formation1. It may result from 
an altered uptake, transfer and secretion of bile 
components, mainly caused by liver injury in the 
absence of mechanical obstruction.
The histological features of cholestasis are bile 
stasis in liver parenchyma and bile ducts plugs; 
bilirubin accumulation into hepatocytes, Kupffer 
cells, and canaliculi in zone 3 as well as ductu-
lar proliferation in zone 1, or bile acid retention 
(“cholate stasis”) may be present1. Blood exami-
nations show the raise at various degrees of se-
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rum bilirubin, alkaline phosphatase (ALP), and 
gamma-glutamyl transpeptidase (GGT), with or 
without increased transaminases levels.
In the liver transplant (LT) setting, cholestasis 
may be classified as extrahepatic, due to mecha-
nical impairment of bile flow (e.g. anastomotic 
strictures, bile stones), or as intrahepatic, associa-
ted with impairment of liver cells or ductular dy-
sfunction. Post LT cholestasis may develop early 
(within 6 months after LT) or late (more than 6 
months after LT), with different etiology accor-
ding to the time elapsed from LT (Table I).
In this review, the main causes of post LT in-
trahepatic cholestasis are discussed, focusing on 
clinical presentation and therapeutic approach.
Early Post-Liver Transplant 
Intrahepatic Cholestasis
In the early post LT period intrahepatic chole-
stasis is common, usually subclinical and self-li-
miting. However, some patients may develop pro-
longed cholestasis and irreversible liver injury, 
leading to re-LT. 
Initial poor graft function (IPGF) and primary 
graft non-function (PNF) may manifest with ear-
ly post LT cholestasis. PNF is an irreversible graft 
dysfunction requiring emergency liver replacement 
within the first 10 days after LT2. It is characterized 
by rapidly rising transaminases, absence of bile pro-
duction, severe coagulation deficit, hypoglycemia, 
high lactate levels, and hemodynamic instability. 
According to the united network of organ sharing 
(UNOS) criteria, PNF is defined by the presence of 
aspartate transaminase (AST) ≥ 5000 IU/L, inter-
national normalized ratio (INR) ≥ 3.0, and acidosis 
(pH ≤ 7.3 and/or lactate concentration ≥ 2× normal). 
Conversely, there is no agreement on the diagnostic 
criteria of IPGF, which is mainly characterized by 
elevation of serum transaminases3-5. 
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The incidence rates are variable, up to 11.8% 
for PNF and to 36% for IPGF, respectively; PNF 
is responsible for 81% of re-transplantations du-
ring the first week after surgery6.
The most frequent causes of early post LT cho-
lestasis, which sometimes lead to PNF and IPGF, 
are mainly related to liver graft preservation 
and size match, infectious complications, acute 
rejection, and drugs.
Ischemia/Reperfusion Injury
Ischemia reperfusion injury (IRI) is the con-
sequence of the inflammatory response triggered 
by the procedures of organ procurement and pre-
servation. Thus, IRI is a kind of “sterile inflam-
mation”, which develops in the absence of any 
microorganism7.
Two major types of IRI can be recognized. 
“Warm” IRI develops in situ during LT surgery 
when hepatic blood supply is temporarily inter-
rupted, and is consequent to hepatocellular dama-
ge. “Cold” IRI, occurs ex vivo during liver graft 
preservation, is caused by hepatic sinusoidal en-
dothelial cells damage and is coupled with warm 
IRI8,9. Other causes of IRI may be sepsis, shock, 
and trauma, which are pathological conditions eli-
citing systemic and liver hypoperfusion that may 
occur in the setting of LT.
In both warm and cold IRI, two stages of liver 
damage can be recognized. The first one is the 
ischemic injury phase, which initiates the process 
of cell death and is characterized by glycogen 
consumption, lack of oxygen, and ATP depletion. 
The subsequent reperfusion injury phase is the 
consequence of the metabolic derangement asso-
ciated with inflammatory damage. Reperfusion 
injury phase can be further distinguished in early 
(or acute), occurring within the first 3 to 6 hours 
post-reperfusion and characterized by the activa-
tion of Kupffer cells, and late (or subacute), with 
massive neutrophil infiltration beginning at 18-24 
hours post-reperfusion9-12. 
IRI is caused by the innate immune respon-
se mediated by pattern recognition receptors 
(PRR)13-16, including Toll-like receptor (TLR) 4, 
TLR9 and the inflammasome17. Different cells of 
the immune system (T lymphocytes and natural 
killer lymphocytes, polymorphonuclear cells) are 
involved in the promotion of IRI, and recent data 
have reported a stimulation of adaptive immune 
response. The “no reflow” phenomenon observed 
after liver reperfusion is a common feature of IRI 
resulting from inflammation; in particular, blood 
flow mechanical obstruction is caused by adhe-
sion of inflammatory cells to the endothelium, 
increased interstitial fluid and endothelial vaso-
constriction18. The activation of the immune sy-
stem leads to a massive production of cytokines, 
chemokines, adhesion molecules, reactive oxygen 
species (ROS), to the activation of the comple-
ment system and to the promotion of autoimmune 
injury, as well as of mitochondrial dysfunction 
triggering cell death programs17. This sustains the 
pro-inflammatory process and produces liver da-
mage.
Treatment
Liver susceptibility to IRI depends on organ 
preservation techniques and is increased by do-
nor starvation, age, and graft steatosis19. Several 
measures can be adopted to reduce the risk of IRI 
in predisposed organs20. Surgical interventions, 
pharmacological agents, and gene therapy are 
the main treatment strategies, which have been 
extensively reviewed elsewhere19. On the whole, 
the use of a vasoprotectors, modulators of the 
renin-angiotensin system, β-blockers, antioxi-
dants, growth factors, tyrosine kinase inhibitors, 
angiotensin II blockers, hydroxy-methylglutaryl 
(HMG)-Coenzyme A (CoA) reductase inhibitors, 
calcium channel blockers, peroxisome prolifera-
tor-activated receptors (PPAR-α) agonists are the 
most innovative approaches reported in literatu-
re, to be distinguished form surgical measures 
widely used in everyday practice (e.g. minimiza-
tion of cold and warm ischemia time, intermittent 
clamping, ischemic preconditioning, the use of 
preservation solutions with specific additives).
Small-For-Size Syndrome 
Living donor LT (LDLT) is a common practice 
for Asian transplant Centers. It has been imple-
mented in selected cases to increase the number 
of available organs in Western Countries and to 
reduce the waiting list period. In practice, donor’s 
liver is splitted in two parts, one of them being 
used as transplantable graft. This procedure may 
be adopted for deceased donors too. To obtain 
an adequate equilibrium between the amount of 
transplanted (recipient) and residual (donor) liver 
tissue, in adult-to-adult LDLT graft size should 
cover 30-40% of the expected recipient’s liver vo-
lume or 0.8-1.0% of the recipient’s body weight21. 
Therefore, the right liver lobe is usually prefer-
red. Living donor liver volumes are calculated 
based on three-dimensional CT scan; the most 
useful estimated parameters are graft volume to 
standard liver volume (SLV) ratio, and graft wei-
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ght-to-recipient body weight ratio (GWBWR)22-25. 
A GWBWR of 0.8% is a widely accepted cut-off 
for minimizing the risk of graft failure26. In the 
case of deceased donors, the body surface area 
index (BSAi) is adopted27. 
Small-for-size syndrome (SFSS) occurs when 
the partial liver graft fails to fulfill the functio-
nal demand of the recipient28. If the hepatocyte 
cellular mass is inadequate for the recipient size, 
the small vascular network of the graft causes a 
discrepancy between accelerated liver regenera-
tion and inadequate supply of oxygen and growth 
factors. This leads to hyperafflux in the portal 
system (portal hyperperfusion), reduction in ar-
terial perfusion (hepatic arterial buffer respon-
se) and sinusoidal microcirculatory disturbances 
causing liver damage and inflammation29-32. 
SFSS encompasses various clinical presenta-
tions, ranging from mild hepatic dysfunction and 
isolated hyperbilirubinemia, to coagulopathy, 
ascites, portal hypertension, prolonged cholesta-
sis, encephalopathy, and irreversible graft failure 
leading to death of the patient in the absence of an 
available organ for re-transplantation. 
Liver biopsy shows diffuse ischemic damage, 
cellular ballooning, and features of cholestasis33. 
Treatment
Treatment is mainly aimed at reducing portal 
hyperperfusion by mechanic procedures (splenic 
artery ligation, splenectomy, portosystemic shun-
ts, extracorporeal continuous portal diversion 
[ECPD]), or medical therapy (splanchnic vaso-
constrictors such as: terlipressin, somatostatin, 
octreotide)34.
Infections
Infectious complications are a common cause 
of morbidity and mortality among LT recipients. 
Bacterial infections are the most frequent (80%), 
followed by viral (20%) and fungal (8%) ones35-
37. Both the reactivation of previous infections 
or the exposition to new infectious agents is 
possible. Concomitant factors may contribute 
to the onset and the evolution of the infective 
episode; they can be recipient-related (advanced 
age, MELD score >30 at LT, acute liver failure, 
malnutrition, > 48 hours stay in intensive care 
unit [ICU], prolonged hospital stay, previous in-
fections, diabetes), donor-related (prolonged ICU 
stay, previous infections, marginal graft), sur-
gery-related (choledochojejunostomy, prolonged 
surgery [> 12 h], re-operation or re-transplanta-
tion, transfusion of more than 15 blood units), 
and related to other post-LT factors (mechanical 
ventilation, level and type of immunosuppres-
sion [e.g. monoclonal and polyclonal antibodies], 
PNF, vascular complications [e.g. hepatic artery 
thrombosis and portal vein thrombosis], biliary 
complications [e.g. ischaemic cholangitis, bi-
liary strictures and fistulae])36-43. 
The type of infection is associated with the 
time from LT. In the first month after surgery 
(early period) opportunistic, donor-derived and 
surgical site infections are usual, whereas at 2-12 
months after LT (intermediate period) opportuni-
stic (Mycobacterium tuberculosis, Pneumocystis, 
Listeria, Cryptococcus, Toxoplasma, Rhodococ-
cus, Nocardia, Legionella, etc.) and community 
acquired infections (flu, urinary tract infections) 
are more frequent. After the first year post LT 
(late period) community acquired infections are 
more likely to occur, whereas opportunistic in-
fections are generally rare44.
Cytomegalovirus (CMV) infection is one of 
the most common viral complications of the ear-
ly-intermediate post LT period, involving about 
30-50% of LT recipients although a delayed on-
set can also be observed44. Either new or reacti-
vated infection may occur. It is characterized by 
virus replication in blood, which can be defined 
as “CMV disease” in the presence of the fol-
lowing associated manifestations: fever >38°C, 
for at least 2 days within a 4-day period, neutro-
penia or thrombocytopenia, and tissue invasion 
with organ dysfunction, including lung, liver, ki-
dney and central nervous system45. According to 
donor and recipient previous contact with CMV, 
the infection can be defined as primary (donor 
positive/recipient negative) or as superinfection 
(donor positive/recipient negative). In the case of 
primary infection, in the absence of prophyla-
xis, over 90% of the recipients develop CMV in-
fection compared to about 25% of the recipients 
in the case of superinfection; in the case of re-
activation of previous infection (donor positive/
recipient negative), around 15% of the recipients 
become ill.
The liver is a regulatory organ in the host de-
fense system, acting as a firewall against syste-
mic diffusion of bacteria and pathogens; during 
infections, several proinflammatory cytokines 
(tumor necrosis factor alpha [TNF-α], interleukin 
[IL]-1, IL-6, and IL-8) are released, altering bile 
acid transport at the sinusoidal and canalicular 
membrane domains46-49.
Cholestasis may precede the development of 
septic complications; bacterial infections usually 
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present with high fever, cholestasis, and positive 
blood cultures. Liver biopsy specimens show bi-
liary tract inflammation with neutrophil infiltra-
tes, bile duct proliferation, and bile plugs50. 
CMV hepatitis usually presents with fever, ja-
undice and increased cholestasis blood test. Liver 
histology shows cholestatic features, microab-
scesses and typical intranuclear “owl’s eye” in-
clusions51. Persistence of CMV has been demon-
strated in liver grafts developing vanishing bile 
duct syndrome and chronic rejection52. Although 
CMV infection may increase alloantigens expres-
sion, making bile ducts more vulnerable to im-
munologic damage53, large studies have failed to 
demonstrate any significant association between 
CMV infection and the development of graft cho-
langiopathy54.
Treatment
The treatment of the infectious complication 
usually resolves cholestasis. 
Acute Cellular Rejection
Although the prevalence of acute cellular 
rejection (ACR) is declining, the current inciden-
ce of clinically significant acute rejection is 10-
40%55.
ACR may be early, usually occurring within 3 
months post LT, or late, occurring after 3 mon-
ths post LT56. In any case, it is triggered by a T 
cells-driven immune response against major hi-
stocompatibility complex (MHC) alloantigens in 
the liver graft. CD4+ and CD8+ T cells but also 
myeloid cells and innate lymphoid cells are ini-
tially involved, but hepatic inflammation leads to 
further recruitment of leukocytes from circula-
tion55,57. Inflammation results in hepatocytes, en-
dothelial cells, and bile ducts damage58-62. 
The association between antibody-mediated 
rejection and ACR has also been a controver-
sial issue in the LT setting. Antibody-mediated 
rejection is a hyperacute rejection characterized 
by graft endothelial damage by complement acti-
vation, with direct injury to the capillary endothe-
lium and activation of inflammatory cells, such as 
natural killer (NK) lymphocytes, macrophages, 
and neutrophils63. 
ACR should be distinguished from hype-
ractue rejection. Donor-specific human alloanti-
bodies (DSAs) against leukocyte antigen (HLA) 
and ABO antibodies are involved in hyperacute 
rejection. DSAs are a well-known risk factor for 
decreased graft survival after kidney and heart 
transplantation. A positive “cross-match”, in-
tended as the detection of antibodies in the re-
cipient’s serum binding to the surface of donor’s 
lymphocytes, is associated with an increased 
risk of hyperacute rejection of the kidney allo-
graft64. 
The liver is relatively resistant to antibodies 
mediated injury due to its wide sinusoidal en-
dothelial surface allowing the absorption of 
circulating antibodies, to its intrinsic ability to 
regenerate and also for the secretion of soluble 
HLA I that binds and inactivate circulating an-
tibodies65-68. These mechanisms of protection al-
low the clearance of preexisting DSAs in 90% 
of presensitized LT-recipients69. However, in pa-
tients with rejection or inflammatory conditions 
involving the liver the exposure of alloantigen 
secondary to tissue injury may trigger the pro-
duction of “de novo” DSAs, similary to what re-
ported for kidney transplant recipients70,71.
The association between a positive cross-ma-
tching and ACR in LT recipients is not constant 
among published studies and is, therefore, diffi-
cult to draw firm conclusions69,72-77. Although the 
presence of inflammation in biopsy specimens 
from patients with a positive cross-match has 
been reported78, no significant difference in tran-
saminases and bilirubin levels, as well as in graft 
and recipient’s survival, was proven compared to 
cross-match negative patients78-81.
Histologically, ACR is classified according to 
Banff criteria82,83. Portal, bile duct and venous en-
dothelial inflammation are the three main featu-
res of ACR, and at least two of them are required 
for the diagnosis. Inflammatory cells in the portal 
spaces are represented by a mixed population of 
lymphocytes (T cells), blast cells, macrophages, 
neutrophils, and eosinophils. Bile ducts appear 
inflamed, with degenerative changes or focal lu-
minal disruption. Centrilobular perivenulitis con-
sists in hepatic venous and perivenular inflam-
mation with perivenular hepatocyte loss. In late 
ACR this “typical” picture is less prominent, but 
central perivenulitis is more marked56,84,85. 
ACR is as always asymptomatic, but jaundice 
can be present. The diagnosis is supposed based 
on the increase in transaminases, bilirubin and 
cholestasis enzymes levels and is confirmed by 
liver biopsy findings.
Treatment
Advances in immunosuppressive therapy have 
significantly increased the success of LT, mini-
mizing the risk of ACR. Histological evidence of 
ACR without any biochemical alteration does not 
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require treatment; on the other hand, when ACR 
is suspected liver biopsy is mandatory to grade 
its severity and to exclude other causes of liver 
damage (e.g. drugs, IRI, infections, recurrent di-
sease) before treatment. The increase of immu-
nosuppression alone is usually effective to treat 
mild ACR; the maintenance of increased levels 
of immunosuppressive drugs associated with cor-
ticosteroid boluses is recommended in modera-
te-severe ACR86. 
Drug Induced Liver Injury
Despite data on the general population are 
scarce, the prevalence of hepatotoxicity among 
patients hospitalized for jaundice has been esti-
mated to range between 2% and 10%87-91 and an 
incidence as high as 2% has been reported in LT 
recipients92. 
Drug induced liver injury (DILI) is an uncom-
mon cause of cholestasis, even if large studies 
confirm that among patients with DILI 20-40% 
may have a cholestatic histological pattern and 
12-20% a mixed hepatocellular/cholestatic pat-
tern93-96. 
Several drugs necessary for LT recipients may 
have hepatotoxic effects and may lead to cholesta-
sis. Therefore, drug induced liver injury (DILI) 
may be a cause of cholestatic damage in both the 
early and the late post LT period.
The most common clinical presentation of cho-
lestatic DILI is the increase in ALP with or wi-
thout jaundice and pruritus. Fever and abdominal 
pain may be present. Diagnosis of DILI is often 
difficult after LT, especially in the early period, 
due to the coexistence of other causes of liver da-
mage. 
Histology is helpful in the differential diagno-
stic process and in the classification of cholestatic 
DILI, which can be distinguished as follows93-95:
• Acute pure cholestasis, presenting with hepa-
tocyte cholestasis, canalicular dilation, and bile 
plugs in the absence of relevant inflammation; 
• Acute cholestatic hepatitis, characterized by 
the association of cholestasis, inflammation 
and sometimes hepatocellular necrosis; 
•  Cholestasis with bile duct injury, when ductu-
lar, cholangiolar, or cholangiolytic damage is 
prevalent and hepatocellular injury is minimal; 
• Vanishing bile duct syndrome.
Cholestatic DILI pattern is defined as an in-
crease in ALP >2 × the upper limit of normal 
and/or with an alanine aminotransferase (ALT)/
ALP ratio <2, whereas a mixed (citonecrotic 
and cholestatic) DILI pattern as an ALT/alka-
line phosphatase ratio greater than 2 and less 
than 5. However, these features are common in 
the early post LT period97,98. The Roussel Uclaf 
Assessment model (RUCAM) may be useful to 
investigate the likelihood of DILI97,98. Further-
more, some drugs have a “signature pattern,” 
as a typical pattern of liver injury may be reco-
gnized after a similar duration of drug intake. 
In the diagnostic workup, online archives and 
web sites are useful tools to investigate drugs 
hepatoxicity99.
It is usually difficult to recognize DILI in the 
LT setting due to the multiple factors potentially 
responsible for liver damage. However, in presen-
ce of unexplained cholestasis, after the exclusion 
of common causes of liver injury and after exten-
sive testing including liver biopsy, DILI should be 
considered as a possible cause.
In the same way as in the general population, 
histological assessment of DILI is challenging in 
LT recipients and may be confounding, due to the 
influence of several other factors, sometimes de-
laying DILI diagnosis. Moreover, the investiga-
tion of medication history, which is mandatory to 
estimate the time to DILI onset, may be difficult 
due to variations in treatment doses and duration 
as well as interruptions/re-start. Conversely, the 
strict biochemical monitoring to which LT reci-
pients are subjected is a potential advantage in the 
early detection of DILI.
Table I. Main causes of post LT intrahepatic cholestasis according to post LT period. 
Early post LT period (<6 months) Late post LT period (≥6 months)
 
Primary non function Chronic rejection
Ischemia/reperfusion injury Infections
Small for size graft Drug induced liver injury
Infections Recurrence of the original disease
Acute rejecton 
Antibodies-mediated rejection 
Drug induced liver injury
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Table II. Classification of medications associated with drug induced liver injury according to the number of reports and to the 
likelihood of use in liver transplant recipients98,123. 
Drugs category A Drugs category B Drugs category C Drugs category D
(≥ 50 Cases) (18-49 Cases)  (4-11 Cases) (1-3 Cases)
Frequently used in LT:
Allopurinol* 
Atorvastatin* 
Diclofenac 
Ibuprofen*
Ticlopidine*
Uncommonly/occasionally
used in LT:
Amiodarone* 
Amoxicillin+calvulanate* 
Rarely used in LT:
Busulfan* 
Carbamazepin*
Dantrolene 
Efavirenz*
Erythromycin* 
Floxuridine* 
Halothane 
Infliximab* 
Ketoconazole* 
Nevirapine* 
Nimesulide* 
Phenytoin* 
Quinidine* 
Rifampin*
Simvastatin* 
Sulfasalazine* 
Sulfonamides* 
Sulindac* 
Thioguanine* 
Valproic Acid* 
Frequently used in LT:
Celecoxib* 
Clopidogrel*
Enalapril*
Esomeprazole 
Fenofibrate* 
Fluvastatin* 
Glibenclamide* 
Lisinopril 
Lovastatin* 
Metformin* 
Naproxen* 
Nifedipine 
Omeprazole
Ranitidine* 
Rosuvastatin*
Uncommonly/occasionally
used in LT:
Amoxicillin* 
Azithromycin* 
Captopril* 
Cefazolin 
Ceftriaxone* 
Ciprofloxacin*
Clarithromycin* 
Fluconazole 
Levofloxacin* 
Propafenone*
Rarely used in LT:
Clindamycin 
Clozapine* 
Doxorubicin 
Duloxetine* 
Etanercept* 
Heparin 
Imatinib* 
Irinotecan 
Itraconazole* 
Moxifloxacin* 
Olanzapine* 
Ofloxacin* 
Paroxetine* 
Phenobarbital* 
Quinine* 
Rivaroxaban 
Sertraline* 
Tamoxifen* 
Thiabendazole* 
Venlafaxine* 
Voriconazole*
Frequently used in LT:
Amlodipine*
Candesartan*
Gemfibrozil*
Gilipizide* 
Glimepiride* 
Irbesartan* 
Ketoprofen* 
Losartan*
Lansoprazole* 
Metronidazole 
Pravastatin* 
Pantoprazole
Ramipril* 
Uncommonly/occasionally
used in LT:
Ampicillin* 
Alfuzosin*
Diltiazem*
Levocetirizine* 
Vancomycin
Verapamil* 
Warfarin* 
 
Rarely used in LT:
Amphotericin B*
Albendazole* 
Bosentan* 
Cephalexin 
Citalopram* 
Cytarabine* 
Daptomycin 
Doxycycline* 
Escitalopram*
Fluoxetine* 
Erlotinib 
Famotidine 
Flavocoxid* 
Fluorouracil* 
Gabapentin* 
Gemcitabine* 
Hydroxyurea 
Indomethacin*
Isotretinoin 
Labetalol 
Levetiracetam 
Linezolid* 
Mesalamines* 
Mirtazapine* 
Mitomycin 
Montelukast* 
Nafcillin 
Natalizumab* 
Nefazodone* 
Norfloxacin* 
Orlistat 
Penicillin G* 
Pioglitazone* 
Pregabalin* 
Procainamide* 
Frequently used in LT:
Acyclovir 
Atenolol* 
Carvedilol* 
Clofibrate*
Enoxaparin 
Fondaparinux 
Hydrochlorotiazide*
Glicazide* 
Propofol 
Rabeprazole* 
Raltegravir 
Repaglinide 
Spironolactone* 
Tamsulosin
Valsartan* 
Uncommonly/Occasionally
used in LT:
Cefaclor 
Cefadroxi
Cefnidir 
Cefepime 
Cefoperazone 
Cefotaxime 
Cefprozil 
Ceftazidime 
Cefuroxime 
Flecainide 
Fosfomycin* 
Imipenem* 
Meropenem* 
Sitagliptin 
Valacyclovir* 
Rarely used in LT:
Acetazolamide* 
Aliskiren* 
Alosetron 
Alprazolam* 
Anastrozole 
Atazanavir* 
Bortezomib* 
Carbenicillin* 
Carboplatin 
Chlorambucil* 
Cisplatin 
Clomipramine* 
Clonazepam* 
Dabigatran 
Dalteparin 
Darbepoetin alfa 
Dasatinib 
Deferoxamine
Donepezil 
Entacapone* 
Ethambutol* 
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The optimization of tailored immunosuppres-
sive drugs regimens have significantly minimized 
the incidence of DILI in LT recipients, but the 
risk is not completely absent and increases when 
complications or other concomitant medical con-
ditions require treatment.
Cyclosporine may have cholestatic effects interfe-
ring with bile formation and leading to hyperbiliru-
binemia and to the formation of biliary sludge100-108. 
The inhibition of ATP-dependent export carriers 
and of the bile salts export pumps in the canalicu-
lar membrane of hepatocytes, together with impair-
ment of biliary secretion of glutathione, are involved 
in cyclosporine-related impairment of canalicular 
bile flow105-107. Similarly to cyclosporine but at a les-
ser extent, tacrolimus has been reported to inhibit 
canalicular bile acids transport and glutathione se-
cretion105,109,110. However, Ericzon et al. reported that 
tacrolimus was able to recover bile acid secretion 
after LT more rapidly than cyclosporine111,112. As re-
gards other immunosuppressive agents, two cases of 
cholestatic liver damage have been reported in two 
renal transplant recipients receiving mycophenolate 
and sirolimus, respectively112,113.
Azathioprine, a purine analogue rarely used as 
immunsosuppressant in the LT setting today, may 
cause damage to the hepatic sinusoidal and venu-
lar endothelial cells, resulting in a variety of cli-
nical, biochemical, and histologic manifestations, 
including cholestasis115-123. 
Among other drugs that may cause a cholesta-
tic syndrome in LT recipients, antifungal agents 
as well as antibiotics have been reported as the 
most common agents of DILI in LT recipients92. 
Pharmacological therapies for cardiovascular 
diseases are frequently employed in LT recipients 
as well as analgesics and antinflammatory anti-
diabetic neurologic, anticoagulant, antiaggregant, 
gastroenterologic and psychotropic medications. 
The main drugs potentially causing DILI, inclu-
ding the cholestatic type, are reported in Table 
II, and are stratified according to the frequency 
of hepatic adverse effects124. Medical therapies 
should not be avoided only for concerns regar-
ding their potential hepatotoxicity, but thorough 
patient evaluation is mandatory to avoid under-
recognized cases of DILI. Particular attention 
should be paid to the use of herbal and dietary 
supplements too, which may be hepatotoxic by 
itself or due to the presence of other ingredients 
and adulterants125,126.
Only 6% of patients with DILI develop chronic 
liver injury127. However, patients with cholestatic 
DILI seem to be more prone to experience chro-
nic liver disease; in a minor part of them, ducto-
penia and vanishing bile duct syndrome with the 
progression to biliary cirrhosis may also occur, 
especially in association with specific drugs128-134. 
Reversal of drug-related vanishing bile duct syn-
drome has also been reported135,136. 
Quetiapine* 
Risperidone* 
Ritonavir* 
Rosiglitazone* 
Sorafenib 
Thalidomide* 
Tolcapone* 
Topiramate 
Trazodone* 
Vincristine 
Zafirlukast
Hydroxychloroquine
Lopinavir* 
Mebendazole 
Mefloquine* 
Metoprolol 
Micafungin 
Nelfinavir 
Ondasetron 
Oxcarbazepine* 
Rifabutin* 
Rilpivirine 
Rivastigmine 
Saquinavir* 
Sildenafil* 
Terbutaline 
Thyroxine 
Tobramycin 
Tolvaptan* 
Triamterene* 
Zileuton 
Table II. Continued. Classification of medications associated with drug induced liver injury according to the number of reports 
and to the likelihood of use in liver transplant recipients98,123. 
Drugs category A Drugs category B Drugs category C Drugs category D
(≥ 50 Cases) (18-49 Cases)  (4-11 Cases) (1-3 Cases)  
*mixed or cholestatic pattern of drug induced liver injury.
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DILI-related mortality ranges between 5% and 
14%93-95. However, in a recent study focused only 
on LT recipients, DILI did not affect the post LT 
outcome as patients did not require re-transplan-
tation and no death was reported92.
Treatment
Immediate withdrawal of the suspected drug 
is the core principle of DILI management. In 
the case of immunosuppressive drugs, dose re-
duction or conversion to other regimens may be 
considered. Specific therapies may be adopted 
for few toxic agents, such as N-acetylcysteine 
for acetaminophen overdose137. N-acetylcysteine 
has been empirically administered to adults with 
DILI due to other agents too, reporting favorable 
results. Corticosteroids may be used in case of 
tyrosine kinase inhibitors-related DILI or in 
case of drug-induced autoimmune-like hepati-
tis, especially when liver injury does not resolve 
after withdrawal of the offending agent. Ursode-
oxycholic acid administration has obtained be-
neficial results in the setting of cholestatic DILI, 
as well as cholestyramin alone or in association 
with antihistamines as regards pruritus relief. 
Silibinin use in the setting of DILI has obtained 
contrasting results, whereas few data on methio-
nine and glutathione are available.
Gastric decontamination (aspiration by lavage, 
charcoal) should be considered in selected cases 
of DILI, such as those related to acteminophen 
overdose, toxic mushrooms, salicylate or to the 
ingestion of other toxic substances.
Late Post-Liver Transplant Intrahepatic 
Cholestasis
The main causes of intrahepatic cholestasis in 
the late post LT period are chronic rejection (CR), 
infections and DILI, which have been extensively 
discussed above.
Exclusion of the recurrence of the original liver 
disease (e.g. hepatitis C virus infection, primary 
sclerosing cholangitis, primary biliary cholangi-
tis) and of extrahepatic conditions inducing cho-
lestasis, such as hepatic artery thrombosis and 
mechanical obstruction, is mandatory to guide 
treatment.
Chronic Rejection 
The prevalence of CR (otherwise called “ducto-
penic rejection”) is 2% in LT recipients, although 
probably  underestimated for the lack of protocols 
for routine histological assessment138,139. It tipical-
ly occurs during the first 12 months after LT but a 
delayed diagnosis is possible, since CR may have 
an indolent course over years140. CR may occur 
in patients with previous episodes of ACR, even 
if this is not a strict requirement141. As like as for 
ACR, a positive cross-matching has been demon-
strated in patients with CR80,142-144. Notably, even 
if data from published studies are contrasting, 
circulating DSAs have been associated with an 
increased risk of developing rejection in patients 
who have weaned immunosuppression.
Loss of bile ducts (vanishing bile duct syn-
drome) at liver histology and obliteration of 
large and medium size arteries are the main-
stay of CR. These pathological alterations are 
due to the infiltration of macrophages (foam 
cells) and inf lammatory cells into the vessel 
wall, leading to fibrosis and, finally to the 
obliteration of arterial lumen with consequent 
ischemic damage.
Histologically, ductopenia should be present 
in more than 50% of portal tracts to make a re-
liable diagnosis of CR145-147. Bile ducts inflam-
mation can be present in the early stages, sub-
siding during time, and bile ducts degeneration 
leads to dysplastic and athrophic features. In the 
centrilobular zone, bilirubinostasis, hepatocyte 
ballooning and loss may be present, evolving in 
centrilobular fibrosis and cirrhosis during time. 
Fibrosis pattern may be veno-centric, which is 
associated with the obliteration of hepatic and 
portal vein branches, periportal/biliary, when 
bile duct inflammation and loss is predominant, 
or centrilobular, which is associated with central 
perivenulitis. Bile duct proliferation and peri-
portal fibrosis are more frequent in cases of late 
presentation, and are suggestive of a prolonged 
course of CR. 
Microscopic vascular abnormalities can be pre-
sent and the small portal tracts may show a reduced 
number of small arterial branches and of other mi-
crovascular channels145-147.
CR may have a long asymptomatic course; pro-
gressive jaundice, with or without ascites, is the 
typical clinical manifestation. 
Treatment
Switch of immunosuppressive therapy or its 
potentiation (combination of two or 3 drugs) are 
the most commonly used approaches. Although 
chronic rejection is sometimes irreversible, re-
transplantation is necessary in only 5% of ca-
ses138,139. 
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Conclusions
Intrahepatic cholestasis in LT recipients is a 
challenge for clinicians, as multiple conditions 
may alter the clinical picture. In the early post LT 
period, cholestasis may be a manifestation of graft 
dyfunction, and a rapid assessment of the possible 
cause is mandatory to start the correct treatment 
rapidly and to avoid the loss of liver graft or its 
irreversible damage. The improvement in surgi-
cal techniques and organ preservation methods as 
well as the progressive shortening of both donor 
and recipient surgical procedures times, have si-
gnificantly reduced the incidence of early post-LT 
cholestasis. Likewise, the optimization of immu-
nosuppressive regimens has minimized the inci-
dence of rejection, of early and late infections and 
of immunosuppressive drugs-related cholestasis. 
In this scenario, DILI remains the most com-
mon cause of post LT cholestasis, especially in 
the late period. Thorough investigation of me-
dical history is mandatory to exclude a possible 
DILI; while the identification of a drug respon-
sible for cholestasis may be very difficult in the 
early postoperative period, it can be easier in the 
late phase, when pharmacological therapy is al-
most stable. However, most of the medications 
are necessary and treatment modifications should 
be done considering potential drug-to-drug inte-
ractions and under close clinical monitoring. 
Liver biopsy maintains a crucial role in the dif-
ferential diagnosis of cholestasis in the LT setting. 
However, as protocol biopsies in asymptomatic 
recipients with normal or near-normal liver tests 
after years from LT are not universally performed, 
liver histology is frequently obtained only when 
ematochemical parameters become abnormal. 
For these reasons, the management of cholesta-
sis in the post LT setting is a complex medical 
issue, and should be performed in collaboration 
with the LT center and devolved to expert hepa-
tologists.
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